Expert Ratings for Nektar Therapeutics
Within the last quarter, Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings:
Benzinga · 05/31 19:06
Nektar Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Nektar Therapeutics (NASDAQ:NKTR) posted sales of $24.82 million. Earnings were up 37.94%, but Nektar Therapeutics still reported an overall loss of $90.39 million.
Benzinga · 05/31 13:47
Jefferies & Co. Assumes Nektar Therapeutics at Hold, Adjust Price Target to $4 From $12
MT Newswires · 05/31 11:14
After a record-breaking decade, biotech is discovering what hard times feel like
An investment climate that's suddenly turned chilly may leave promising companies out in the cold.
American City Business Journals · 05/27 12:00
Research Alert: CFRA Maintains Hold Opinion On Shares Of Nektar Therapeutics
MT Newswires · 05/25 10:21
BRIEF-Nektar Therapeutics Says Interim Assessment Committee Reviewed Interim Data From Ongoing Phase 2 Study Of NKTR-358 · 05/23 13:25
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 05/16 18:09
Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track
Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.
Zacks · 05/06 14:07
Nektar Therapeutics Q1 EPS $(0.49) Up From $(0.68) YoY, Sales $24.80M Up From $23.65M YoY
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.49) per share. This is a 27.94 percent increase over losses of $(0.68) per share from the same period last year. The company reported $24.80 million in
Benzinga · 05/05 22:15
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:55
Nektar Therapeutics GAAP EPS of -$0.49 beats by $0.21, revenue of $24.8M misses by $0.09M
Nektar Therapeutics press release (NASDAQ:NKTR): Q1 GAAP EPS of -$0.49 beats by $0.21. Revenue of $24.8M (+4.9% Y/Y) misses by $0.09M. Cash and investments in marketable securities at March 31, 2022
Seekingalpha · 05/05 20:49
BRIEF-Nektar Therapeutics Reports First Quarter 2022 Financial Results · 05/05 20:45
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q1 Revenue $24.8M
MT Newswires · 05/05 16:59
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.35% and 9.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 12:15
BRIEF-Nektar Therapeutics - On April 26, Approved Certain Steps In Connection With New Strategic Reorganization Plan And Cost Restructuring Plan · 05/02 21:09
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 04/28 19:02
Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?
Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.
Zacks · 04/27 16:00
After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring
Benzinga · 04/26 15:43
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 04/26 13:04
Nektar to reduce workforce by 70%
Shares of Nektar Therapeutics were down 5.7% in premarket trading on Tuesday, the day after the company said it will lay off 70% of its workforce. As of Dec. 31, the company employed 740 workers. Nektar last week halted development of bempegaldesleukin, an... · 04/26 12:53
Webull provides a variety of real-time NKTR stock news. You can receive the latest news about Nektar Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About NKTR
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.